Showing results (111-120 of 304) with videos related to

Sort By:
Pageof 31
Therapeutic Drug Monitoring|February 17, 2024
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS MethodBianca Posocco, Martina Zanchetta, Marco Orleni, et al.
Frontiers in Immunology|October 24, 2024
Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case seriesSara Gagno, Bianca Posocco, Marco Orleni, et al.
Melanoma Research|February 16, 2013
Expression of thymidine phosphorylase and cyclooxygenase-2 in melanomaAlessandro M Minisini, Gaetano Pascoletti, Donatella Intersimone, et al.
Oncology Reports|July 16, 2004
BRCA2 germline mutations in primary cancer of the fallopian tubeSara Casarsa, Fabio Puglisi, Francesco Baudi, et al.
JCO Global Oncology|January 3, 2025
Role of Social Media for Medical Oncologists and Medical Oncology Fellows (SMARTY): An Italian Cross-Sectional StudyElena Battaiotto, Carmine Valenza, Mattia Garutti, et al.
Expert Review of Anticancer Therapy|June 10, 2024
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, et al.
Journal of Gynecology Obstetrics and Human Reproduction|January 8, 2026
Evaluating the role of secondary surgery and PARP inhibition in platinum-sensitive ovarian cancer relapseStefano Fucina, Nicolò Clemente, Anna Del Fabro, et al.
Melanoma Research|September 10, 2025
Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancerStefano Fucina, Lucia Lerda, Anna Del Fabro, et al.
Frontiers in Pharmacology|September 23, 2024
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactionsElena Peruzzi, Bianca Posocco, Lorenzo Gerratana, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 14, 2007
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weeklyGiacomo Cartenì, Laura Giannetta, Giovanni Ucci, et al.
Pageof 31